A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

Summary

This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.

Timeline

Start

2021-03-30

Primary completion

2022-05-05

Completion

2022-05-05

Drugs

Indications